The potential market for a promising new hepatitis drug could be significant for Arrowhead Research, CEO Chris Anzalone said Monday.
"Hepatitis B is a tremendous unmet medical need. What we have is somewhere between 350 and 400 million people in the world that have chronic Hepatitis B infection. That's one in 20 people on the planet, and there's no cure right now," Anzalone said on CNBC's "Fast Money."
Gilead's premier drug for hepatitis C, Sovaldi, is on pace to exceed $10 billion in sales in 2014 and cures more than 80 percent of patients with few side effects.